Garnett C - Search Results

1

Heart Rate Correction of the J-to-Tpeak Interval.

Hnatkova K, Vicente J, Johannesen L, Garnett C, Strauss DG, Stockbridge N, Malik M. Hnatkova K, et al. Among authors: garnett c. Sci Rep. 2019 Oct 21;9(1):15060. doi: 10.1038/s41598-019-51491-4. Sci Rep. 2019. PMID: 31636317 Free PMC article.

2

Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.

Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornøe CW, Wang Y, Zhu H, Gobburu JV. Garnett CE, et al. J Clin Pharmacol. 2008 Jan;48(1):13-8. doi: 10.1177/0091270007307881. J Clin Pharmacol. 2008. PMID: 18094216 Review.

3

Thorough QT Studies: Questions and Quandaries.

Malik M, Garnett CE, Zhang J. Malik M, et al. Drug Saf. 2010 Jan 1;33(1):1-14. doi: 10.2165/11319160-000000000-00000. Drug Saf. 2010. PMID: 20000862 Review.

4

Assessing electrocardiographic data quality and possible replacement of pharmacologic positive control in thorough QT/QTc studies by investigations of drug-free QTc stability.

Malik M, Zhang J, Johannesen L, Hnatkova K, Garnett C. Malik M, et al. Among authors: garnett c. Heart Rhythm. 2011 Nov;8(11):1777-85. doi: 10.1016/j.hrthm.2011.06.016. Epub 2011 Jun 16. Heart Rhythm. 2011. PMID: 21699874 No abstract available.

5

Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects.

Garnett CE, Zhu H, Malik M, Fossa AA, Zhang J, Badilini F, Li J, Darpö B, Sager P, Rodriguez I. Garnett CE, et al. Am Heart J. 2012 Jun;163(6):912-30. doi: 10.1016/j.ahj.2012.02.023. Epub 2012 May 4. Am Heart J. 2012. PMID: 22709743 Review.

6

Practice and challenges of thorough QT studies.

Stockbridge N, Zhang J, Garnett C, Malik M. Stockbridge N, et al. Among authors: garnett c. J Electrocardiol. 2012 Nov-Dec;45(6):582-7. doi: 10.1016/j.jelectrocard.2012.07.020. Epub 2012 Sep 19. J Electrocardiol. 2012. PMID: 22999322 Review.

7

Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?

Stockbridge N, Morganroth J, Shah RR, Garnett C. Stockbridge N, et al. Among authors: garnett c. Drug Saf. 2013 Mar;36(3):167-82. doi: 10.1007/s40264-013-0016-z. Drug Saf. 2013. PMID: 23417505 Review.

8

Improving the assessment of heart toxicity for all new drugs through translational regulatory science.

Johannesen L, Vicente J, Gray RA, Galeotti L, Loring Z, Garnett CE, Florian J, Ugander M, Stockbridge N, Strauss DG. Johannesen L, et al. Among authors: garnett ce. Clin Pharmacol Ther. 2014 May;95(5):501-8. doi: 10.1038/clpt.2013.238. Epub 2013 Dec 12. Clin Pharmacol Ther. 2014. PMID: 24336137

9

The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?".

Darpo B, Sarapa N, Garnett C, Benson C, Dota C, Ferber G, Jarugula V, Johannesen L, Keirns J, Krudys K, Ortemann-Renon C, Riley S, Rogers-Subramaniam D, Stockbridge N. Darpo B, et al. Among authors: garnett c. Ann Noninvasive Electrocardiol. 2014 Jan;19(1):70-81. doi: 10.1111/anec.12128. Epub 2013 Dec 30. Ann Noninvasive Electrocardiol. 2014. PMID: 24372708 Free PMC article. Review.

10

Electrocardiographic data quality in thorough QT/QTc studies.

Johannesen L, Garnett C, Malik M. Johannesen L, et al. Among authors: garnett c. Drug Saf. 2014 Mar;37(3):191-7. doi: 10.1007/s40264-014-0140-4. Drug Saf. 2014. PMID: 24554349

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

172 results

Search Page